Is Regeneron In Trouble After Sales Declined 40% In a Single Quarter?
Regeneron (NASDAQ: REGN) got a big boost last year due to COVID-19. But with demand for its antibody cocktail now declining, the company suffered a big drop in quarter-over-quarter sales. But it wasn't only Regeneron's COVID product that saw a slide in demand; other headlining products declined as well.
What does all this mean for the company's future? Let's take a closer look to see if Regeneron's stock is in trouble after underwhelming first-quarter results and determine if this healthcare company is a good buy.
Image source: Getty Images.
Source Fool.com
